凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海医药:2012年第三季度报告

公告日期 2012-10-30
股票简称:上海医药 股票代码:601607
上海医药集团股份有限公司
  (A 股股票代码:601607)
  (H 股股票代码: 02607)


  2012 年第三季度报告
601607,02607                                      上海医药集团股份有限公司 2012 年第三季度报告




                                        目录

§1 重要提示 ......................................................................... 1

§2 公司基本情况 ..................................................................... 1

§3 重要事项 ......................................................................... 3

§4 附录 ............................................................................. 6
601607,02607                                         上海医药集团股份有限公司 2012 年第三季度报告



§1重要提示
1.1 公司全体董事出席了于 2012 年 10 月 29 日召开的第四届董事会第二十五次会议,会议通过的决议
包括批准本公司截至 2012 年 9 月 30 日止九个月之第三季度业绩。

1.2 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、
误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。

1.3 公司第三季度财务报告未经审计。

1.4
公司负责人姓名                               周杰
主管会计工作负责人姓名                       徐国雄
会计机构负责人(会计主管人员)姓名           沈波
公司负责人周杰先生、主管会计工作负责人徐国雄先生及会计机构负责人(会计主管人员)沈波先生
声明:保证本季度报告中财务报告的真实、完整。

1.5 释义
本报告中,除非文义另有所指,相关财务数据均为根据中国企业会计准则等规定编制,下列词语具有
下述含义:
  “本公司”、“公司”或“上海
                               指   上海医药集团股份有限公司
  医药”
  “公司章程”或“章程”       指   (经不时修订的)上海医药的公司章程
  “报告期”                   指   2012 年 7 月 1 日至 2012 年 9 月 30 日的 3 个月
  “同比”                     指   与上年同期比较
  “股份”                     指   上海医药每股面值人民币 1.00 元的股份,包括 A 股和 H 股
                                    在上海证券交易所上市、并以人民币买卖的本公司内资股,
  “A 股”                     指
                                    每股面值人民币 1.00 元
                                    在香港联合交易所有限公司上市、并以港元买卖的本公司
  “H 股”                     指
                                    外资股,每股价值人民币 1.00 元
  “人民币”                   指   中国法定货币人民币
  “港元”                     指   香港法定货币港元
                                    中华人民共和国,除另有所指外,在本报告内“中国”一
  “中国”                     指
                                    词不包括香港、澳门及台湾
  “香港”                     指   香港特别行政区
  “上实集团”                 指   上海实业(集团)有限公司
  “上海上实”                 指   上海上实(集团)有限公司
  “上药集团”                 指   上海医药(集团)有限公司
  “上海盛睿”                 指   上海盛睿投资有限公司

§2 公司基本情况
2.1 主要会计数据及财务指标
特别说明:
    1、本公司 2012 年 1-9 月累计实现营业收入人民币 511.47 亿元,较上年同期增长 27.01%。实现
归属于母公司股东的净利润人民币 15.47 亿元,较上年同期扣除因广东天普生化医药股份有限公司不
再纳入合并报表产生的一次性投资收益后的净利润人民币 13.79 亿元,同比增长 12.15%。
    2、本公司 2012 年 1-9 月,分销业务实现营业收入(合并抵销前)人民币 439.30 亿元,较上年同
期增长 29.82%。
    3、本公司 2012 年 1-9 月,工业业务实现营业收入(合并抵销前)人民币 73.44 亿元,较上年同
期增长 9.25%。

                                             1
601607,02607                                        上海医药集团股份有限公司 2012 年第三季度报告



                                                                                    币种:人民币
                                                                                本报告期末比
                                           本报告期末        上年度期末         上年度期末增
                                                                                      减(%)
 总资产(千元)                            51,129,667.41       47,667,822.92                 7.26
 所有者权益(或股东权益)(千元)          24,066,067.40       23,078,472.25                 4.28
 归属于上市公司股东的每股净资产(元/股)           8.95               8.58                 4.28
                                                 年初至报告期期末               比上年同期增
                                                    (1-9 月)                       减(%)
 经营活动产生的现金流量净额(千元)                               707,211.17                56.00
 每股经营活动产生的现金流量净额(元/股)                            0.2630                56.00
                                                                                本报告期比上
                                             报告期       年初至报告期期末
                                                                                  年同期增减
                                           (7-9 月)      (1-9 月)
                                                                                      (%)
 归属于上市公司股东的净利润(千元)            399,120.50        1,546,836.51               11.38
 基本每股收益(元/股)                           0.1485              0.5753               11.38
 扣除非经常性损益后的基本每股收益(元/
                                                 0.1361               0.5340             9.76
 股)
 稀释每股收益(元/股)                           0.1485               0.5753           11.38
                                                                                增加 0.12 个
 加权平均净资产收益率(%)                         1.67                 6.56
                                                                                  百分点
 扣除非经常性损益后的加权平均净资产收益                                         增加 0.09 个
                                                   1.53                 6.09
 率(%)                                                                          百分点

扣除非经常性损益项目和金额:
                                                                    单位:千元 币种:人民币
                                                                      年初至报告期期末金额
                               项目
                                                                          (1-9 月)
 非流动资产处置损益                                                               27,973.44
 计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家
                                                                                    84,850.57
 政策规定、按照一定标准定额或定量持续享受的政府补助除外
 除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资
 产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资                        453.85
 产、交易性金融负债和可供出售金融资产取得的投资收益
 单独进行减值测试的应收款项减值准备转回                                             9,682.90
 除上述各项之外的其他营业外收入和支出                                              21,561.49
 所得税影响额                                                                     -29,600.14
 少数股东权益影响额(税后)                                                        -3,932.69
                               合计                                               110,989.42

2.2 报告期末股东总人数及前十名无限售条件股东持股情况表
                                                                                  单位:股
 报告期末股东总数(户)                                    107,125(A 股);3,438(H 股)
                            前十名无限售条件流通股股东持股情况
                                                        期末持有无
                    股东名称(全称)                    限售条件流          股份种类
                                                        通股的数量
 HKSCC NOMINEES LIMITED                                 748,463,520     境外上市外资股
 上海盛睿                                               162,399,040       人民币普通股
 申能(集团)有限公司                                       81,199,520      人民币普通股

                                            2
601607,02607                                           上海医药集团股份有限公司 2012 年第三季度报告



 上药集团(注)                                              56,917,288         人民币普通股
                                                                            境外上市外资股及人
 上实集团及其全资附属子公司                                  44,776,990
                                                                                民币普通股
中国工商银行-广发聚丰股票型证券投资基金                   28,247,231           人民币普通股
中国工商银行-景顺长城精选蓝筹股票型证券投资基金           17,499,705           人民币普通股
中国人寿保险股份有限公司-分红-个人分红-005L-
                                                           14,012,296      人民币普通股
FH002 沪
中国建设银行-国泰金马稳健回报证券投资基金                 11,200,000      人民币普通股
太平人寿保险有限公司-分红-团险分红                       10,906,236      人民币普通股
注:上药集团持有的 56,917,288 股无限售条件 A 股股份自愿锁定 36 个月至 2013 年 2 月 10 日。

§3 重要事项
3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因
√适用   □不适用
 合并资产负债表项目   2012 年 9 月 30 日   2011 年 12 月 31 日    变动比例         变动原因
                                                                               本报告期销售收
 应收账款             14,824,836,654.71     10,606,364,608.21        39.77%    入增长致应收账
                                                                               款增加
                                                                               本报告期收回计
 应收利息                   8,991,386.03          30,646,890.65     -70.66%
                                                                               提的利息收入
                                                                               本报告期收回股
 应收股利                   9,426,270.92          15,990,542.89     -41.05%
                                                                               利收入
                                                                               本报告期期末留
 其他流动资产             34,548,454.73        144,481,908.13       -76.09%
                                                                               抵进项税额减少
                                                                               本报告期在建工
 在建工程                416,812,756.01        311,674,395.13        33.73%
                                                                               程投入增加
                                                                               本报告期下属子
 应付股利                122,975,673.07           72,935,928.93      68.61%    公司宣告发放现
                                                                               金股利
                                                                               本报告期收到动
 其他非流动负债          583,275,100.33        280,122,157.89       108.22%
                                                                               迁补偿款增加
                                                                               本报告期境外子
 外币报表折算差额        -35,422,611.93        -10,148,525.93      -249.04%    公司汇率变动所
                                                                               致
   合并利润表项目       2012 年 1-9 月         上年同期数         变动比例         变动原因
                                                                               本报告期存款利
 财务费用-净额           154,806,069.23        328,929,885.76       -52.94%
                                                                               息收入增加
                                                                               本报告期计提坏
 资产减值损失             11,654,836.68            4,377,201.29     166.26%
                                                                               账增加
                                                                               本报告期一次性
 投资收益                298,046,525.53        917,504,119.74       -67.52%
                                                                               投资收益减少
                                                                               本报告期转让可
 其他综合收益            -24,364,353.01        -66,111,509.75        63.15%    供出售金融资产
                                                                               减少
 合并现金流量表项目     2012 年 1-9 月         上年同期数         变动比例         变动原因
 经营活动产生的现金                                                            本报告期货款回
                         707,211,166.42        453,331,183.39        56.00%
 流量净额                                                                      笼增加
 投资活动产生的现金                                                            本报告期收购子
                        -656,591,455.93     -2,628,448,388.73        75.02%
 流量净额                                                                      公司支付对价减

                                              3
601607,02607                                                              上海医药集团股份有限公司 2012 年第三季度报告



                                                                                                          少

                                                                                                          上年同期境外发
 筹资活动产生的现金
                                -1,719,765,230.76            10,445,527,942.99           -116.46%         行股票募集资金
 流量净额
                                                                                                          增加

3.2 重大事项进展情况及其影响和解决方案的分析说明
□适用 √不适用

3.3 公司、股东及实际控制人承诺事项履行情况
√适用 □不适用
 承   承                                   是否   是否
           承
 诺   诺                                   有履   及时   如未能及时履行应说明      如未能及时履行应说明        本报告期取得的进
           诺   承诺内容
 背   类                                   行期   严格   未完成履行的具体原因      下一步计划                  展
           方
 景   型                                   限     履行
 与
                自重大资产重组涉及的
 重        上
                非公开发行完成之日起
 大        药
                36 个月内,不转让其拥      是     是     /                         /                           /
 资        集
      股        有权益的上海医药股
 产        团
      份        份。
 重
      限
 组
      售        自重大资产重组涉及的
 相        上
                非公开发行完成之日起
 关        海
                36 个月内,不转让其拥      是     是     /                         /                           /
 的        上
                有权益的上海医药股
 承        实
                份。
 诺
      解   上   根据《上海市医药股份       是     否     根据上药集团 2012 年 5    上海医药将与上药集团        通过吸收合并重组
      决   药   有限公司换股吸收合                       月 10 日出具的《关于在    及各方积极协调配合,进      进入上海医药的土
      土   集   并、发行股份购买资产                     上海医药集团股份有限      一步对瑕疵土地房产进        地面积 220.38 万平
      地   团   暨关联交易报告书》:                     公司 2010 年重大资产重    行规范。                    方米、房产面积为
      等        上药集团承诺督促有关                     组中承诺涉及的土地房                                  109.72 万平方米,其
      产        单位推进相关不规范土                     产问题的说明》,上药集                                中:不规范土地
      权        地、房产的规范工作,                     团对截至本报告期末的                                  120,262.82 平方米、
      瑕        即通过补交出让金、补                     瑕疵土地共 22 幅、面积                                不 规 范 房 产
      疵        办房地产权证,或协商                     87,730.52 平方米;瑕疵                                129,280.22 平方米。
                达成政府收储土地安排                     房 产 共 25 处 、 面 积                               从吸收合并重组完
                等方式,若在 2011 年 6                   87,310.99 平方米发出了                                成后开始,截至本报
                月 30 日前不能完成前述                   收购意向,经上海医药及                                告期末,上海医药通
                规范,上药集团承诺将                     其附属企业尽最大努力                                  过补交土地出让金、
                按照届时评估价以现金                     与各方(包括但不限于少                                股权转让、政府收储
                方式收购等方式尽快解                     数股东、政府机构及其职                                等方式已先后规范
                决该等土地、房产存在                     能部门等)进行沟通,因                                土地 32,532.30 平方
                的瑕疵问题,在相关房                     集体工业用地、持续经营                                米 , 规 范 房 产
                地产得到最终规范前,                     和资产完整性需要以及                                  41,969.23 平方米。
                上药集团需保证有关单                     少数股东不同意等原因,
                位能够按现状使用该处                     无法将该等土地及房产
                房地产。如有关单位因                     出让。
                权属不规范而额外支付
                成本、费用、停工停产
                损失(若有)等,上药
                集团予以弥补。
                2012 年 5 月 10 日,上药
                集团出具了《关于在上
                海医药集团股份有限公
                司 2010 年重大资产重组
                中承诺涉及的土地房产
                问题的说明》,并由上
                海医药于 2012 年 5 月 11
                日予以公告。


3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示
及原因说明
□适用 √不适用


                                                               4
601607,02607                                         上海医药集团股份有限公司 2012 年第三季度报告



3.5 报告期内现金分红政策的执行情况
    本公司根据《公司章程》规定的现金分红政策进行分红。报告期内,公司执行了 2011 年度利润分
配方案,方案为:以 2011 年 12 月 31 日股本总数 2,688,910,538 股为基数,向全体股东实施每 10 股
派发现金红利人民币 1.60 元(含税),派发现金红利总额为人民币 430,225,686.08 元,占当年税后
利润的 21.07%。实施利润分配后,公司结存未分配利润为人民币 4,766,034,971.50 元。本报告期不
进行资本公积金转增股本。该利润分配方案已于 2012 年 7 月 25 日实施完毕。


                                                                    上海医药集团股份有限公司
                                                                              法定代表人:周杰
                                                                            2012 年 10 月 30 日




                                              5
601607,02607                                         上海医药集团股份有限公司 2012 年第三季度报告



§4附录
4.1
                                      合并资产负债表
                                     2012 年 9 月 30 日
编制单位: 上海医药集团股份有限公司
                                                 单位:元 币种:人民币 审计类型:未经审计
                 项目                            期末余额                  年初余额
 流动资产:
     货币资金                                    13,208,934,004.13         14,850,053,673.66
     结算备付金
     拆出资金
     交易性金融资产                                   2,984,846.88              2,658,764.00
     应收票据                                     1,097,350,916.79            971,206,337.81
     应收账款                                    14,824,836,654.71         10,606,364,608.21
     预付款项                                       477,468,753.34            481,781,725.51
     应收保费
     应收分保账款
     应收分保合同准备金
     应收利息                                         8,991,386.03              30,646,890.65
     应收股利                                         9,426,270.92              15,990,542.89
     其他应收款                                     512,524,863.80             595,158,005.45
     买入返售金融资产
     存货                                         8,785,139,443.11          8,297,482,726.00
     一年内到期的非流动资产
     其他流动资产                                    34,548,454.73            144,481,908.13
       流动资产合计                              38,962,205,594.44         35,995,825,182.31
 非流动资产:
     发放委托贷款及垫款
     可供出售金融资产                                19,195,737.46              18,470,202.06
     持有至到期投资
     长期应收款
     长期股权投资                                 2,755,576,235.00          2,618,839,435.97
     投资性房地产                                   348,505,210.82            384,547,928.00
     固定资产                                     3,681,691,442.49          3,724,982,688.75
     在建工程                                       416,812,756.01            311,674,395.13
     工程物资                                         2,931,207.84              2,930,915.32
     固定资产清理
     生产性生物资产                                       718,216.22               718,216.22
     油气资产
     无形资产                                     1,418,569,144.98          1,276,234,104.08
     开发支出
     商誉                                         3,177,020,754.35          2,988,894,594.17
     长期待摊费用                                   115,458,201.51             89,151,047.28
     递延所得税资产                                 172,218,870.11            178,629,271.19
     其他非流动资产                                  58,764,041.00             76,924,942.82
       非流动资产合计                            12,167,461,817.79         11,671,997,740.99
           资产总计                              51,129,667,412.23         47,667,822,923.30
 流动负债:
     短期借款                                     4,865,456,825.49          5,674,728,861.48

                                             6
601607,02607                                     上海医药集团股份有限公司 2012 年第三季度报告



    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                   2,548,272,220.12         2,095,911,882.63
    应付账款                                  12,722,713,855.09        10,563,558,378.10
    预收款项                                     338,347,879.12           371,259,855.64
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                 375,763,769.13           331,375,573.00
    应交税费                                     399,038,766.21           393,121,382.16
    应付利息                                      18,152,555.76            18,004,355.70
    应付股利                                     122,975,673.07            72,935,928.93
    其他应付款                                 1,226,766,849.70         1,334,284,030.03
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                           830,000.00                730,000.00
    其他流动负债
      流动负债合计                            22,618,318,393.69        20,855,910,247.67
非流动负债:
    长期借款                                      43,641,158.61             52,311,466.84
    应付债券
    长期应付款
    专项应付款                                   190,641,149.03           160,382,718.27
    预计负债                                      55,162,392.24            71,342,961.55
    递延所得税负债                               285,191,334.43           266,287,608.24
    其他非流动负债                               583,275,100.33           280,122,157.89
      非流动负债合计                           1,157,911,134.64           830,446,912.79
        负债合计                              23,776,229,528.33        21,686,357,160.46
所有者权益(或股东权益):
    实收资本(或股本)                         2,688,910,538.00         2,688,910,538.00
    资本公积                                  14,449,441,582.50        14,490,121,084.23
    减:库存股
    专项储备
    盈余公积                                     713,328,494.07            713,328,494.07
    一般风险准备
    未分配利润                                 6,249,809,401.20         5,196,260,657.58
    外币报表折算差额                             -35,422,611.93           -10,148,525.93
    归属于母公司所有者权益合计                24,066,067,403.84        23,078,472,247.95
    少数股东权益                               3,287,370,480.06         2,902,993,514.89
          所有者权益合计                      27,353,437,883.90        25,981,465,762.84
        负债和所有者权益总计                  51,129,667,412.23        47,667,822,923.30
公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波




                                          7
601607,02607                                         上海医药集团股份有限公司 2012 年第三季度报告



                                     母公司资产负债表
                                     2012 年 9 月 30 日
编制单位: 上海医药集团股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                 项目                             期末余额                年初余额
 流动资产:
     货币资金                                     4,747,294,022.14          8,608,621,502.40
     交易性金融资产
     应收票据
     应收账款                                        12,086,873.08              12,086,873.08
     预付款项
     应收利息                                         8,480,274.27             28,980,841.91
     应收股利                                       138,890,140.99            122,359,752.76
     其他应收款                                   4,657,103,290.87          1,510,001,342.08
     存货
     一年内到期的非流动资产
     其他流动资产                                     6,204,688.91              2,181,149.51
       流动资产合计                               9,570,059,290.26         10,284,231,461.74
 非流动资产:
     可供出售金融资产                                     947,832.86             1,221,886.77
     持有至到期投资
     长期应收款
     长期股权投资                                12,984,282,754.10         12,727,701,829.90
     投资性房地产                                    55,081,622.54             56,206,079.54
     固定资产                                       136,389,745.54            128,685,929.68
     在建工程                                        15,178,158.49             30,879,238.20
     工程物资
     固定资产清理
     生产性生物资产
     油气资产
     无形资产                                        26,298,990.30              26,712,151.87
     开发支出
     商誉
     长期待摊费用                                    18,669,334.59               4,590,073.23
     递延所得税资产
     其他非流动资产
       非流动资产合计                            13,236,848,438.42         12,975,997,189.19
          资产总计                               22,806,907,728.68         23,260,228,650.93
 流动负债:
     短期借款                                       400,000,000.00             946,000,000.00
     交易性金融负债
     应付票据
     应付账款                                         7,206,276.23              10,515,486.23
     预收款项                                         4,207,189.17               4,207,189.17
     应付职工薪酬                                                               14,205,796.95
     应交税费                                         4,701,903.82               6,532,500.72
     应付利息                                           488,933.33               1,566,822.21
     应付股利
     其他应付款                                   1,959,232,335.02          1,990,860,834.52


                                             8
601607,02607                                          上海医药集团股份有限公司 2012 年第三季度报告



     一年内到期的非流动负债
     其他流动负债
       流动负债合计                            2,375,836,637.57     2,973,888,629.80
非流动负债:
     长期借款
     应付债券
     长期应付款
     专项应付款                                   19,276,018.65        26,997,719.83
     预计负债
     递延所得税负债                                  203,321.35           271,834.84
     其他非流动负债                                2,405,236.72         1,280,296.22
       非流动负债合计                             21,884,576.72        28,549,850.89
         负债合计                              2,397,721,214.29     3,002,438,480.69
所有者权益(或股东权益):
     实收资本(或股本)                        2,688,910,538.00     2,688,910,538.00
     资本公积                                 16,370,039,476.24    16,371,133,200.31
     减:库存股
     专项储备
     盈余公积                                    342,219,268.97       342,219,268.97
     一般风险准备
     未分配利润                                1,008,017,231.18       855,527,162.96
所有者权益(或股东权益)合计                  20,409,186,514.39    20,257,790,170.24
         负债和所有者权益(或股东权益)
                                              22,806,907,728.68    23,260,228,650.93
总计
公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波

4.2
                                         合并利润表
编制单位: 上海医药集团股份有限公司
                                                         单位:元 币种:人民币 审计类型:未经审计
                   本期金额              上期金额        年初至报告期期末金 上年年初至报告期期
      项目
                 (7-9 月)           (7-9 月)           额(1-9 月)      末金额(1-9 月)
 一、营业总
               17,526,107,760.10     14,376,031,043.37    51,147,303,313.56       40,269,146,680.95
 收入
      其中:
               17,526,107,760.10     14,376,031,043.37    51,147,303,313.56       40,269,146,680.95
 营业收入

 利息收入

 已赚保费

 手续费及佣
 金收入
 二、营业总
               17,012,792,301.73     13,905,431,743.96    49,241,391,125.37       38,783,995,351.54
 成本
      其中:
               15,285,236,192.60     12,392,737,368.46    44,267,664,139.75       34,380,238,238.36
 营业成本

 利息支出


                                             9
601607,02607                                 上海医药集团股份有限公司 2012 年第三季度报告



 手续费及佣
 金支出

 退保金

 赔付支出净
 额

 提取保险合
 同准备金净
 额

 保单红利支
 出

 分保费用

 营业税金及    45,266,347.87    46,235,566.25        137,021,463.35          134,000,751.14
 附加

               971,783,306.62   787,900,255.61    2,905,166,754.64         2,360,913,115.65
 销售费用

               609,813,479.31   549,155,039.06    1,765,077,861.72         1,575,536,159.34
 管理费用

               106,227,621.97   133,441,849.47       154,806,069.23          328,929,885.76
 财务费用

 资产减值损    -5,534,646.64    -4,038,334.89         11,654,836.68            4,377,201.29
 失
     加:公
 允价值变动
 收益(损失      -258,832.52      -552,388.00             326,082.88             -996,168.00
 以“-”号
 填列)
          投
 资收益(损
               61,722,229.38    67,465,029.78        298,046,525.53          917,504,119.74
 失以“-”
 号填列)

 其中:对联
 营企业和合    46,829,343.89    39,019,663.60        259,576,430.68          262,555,893.07
 营企业的投
 资收益
          汇
 兑收益(损
 失以“-”
 号填列)
 三、营业利
 润(亏损以
               574,778,855.23   537,511,941.19    2,204,284,796.60         2,401,659,281.15
 “-”号填
 列)
      加:营   43,393,004.48    65,512,458.62        130,598,058.07          116,890,629.02

                                     10
601607,02607                                         上海医药集团股份有限公司 2012 年第三季度报告



业外收入
     减:营
                    8,611,849.65      22,406,769.06      27,656,989.44                38,636,549.68
业外支出
       其
中:非流动
                    2,675,292.42       6,792,934.98       8,601,319.84                14,033,138.43
资产处置损

四、利润总
额(亏损总
                  609,560,010.06     580,617,630.75  2,307,225,865.23              2,479,913,360.49
额以“-”
号填列)
     减:所
                  109,727,153.26     133,794,503.45    464,652,797.12                483,819,084.66
得税费用
五、净利润
(净亏损以
                  499,832,856.80     446,823,127.30  1,842,573,068.11              1,996,094,275.83
“-”号填
列)
     归属于
母公司所有        399,120,496.01     358,353,719.94  1,546,836,506.85              1,713,022,704.99
者的净利润
     少数股
                  100,712,360.79      88,469,407.36    295,736,561.26                283,071,570.84
东损益
六、每股收
益:
     (一)
基本每股收                0.1485             0.1333             0.5753                         0.7353

     (二)
稀释每股收                0.1485             0.1333             0.5753                         0.7353

七、其他综
                   -6,587,132.40        -634,959.39    -24,364,353.01                -66,111,509.75
合收益
八、综合收
                  493,245,724.40     446,188,167.91  1,818,208,715.10              1,929,982,766.08
益总额
     归属于
母公司所有
                  392,533,363.61     356,072,067.30  1,522,335,755.50              1,646,911,195.24
者的综合收
益总额
     归属于
少数股东的
                  100,712,360.79      90,116,100.61    295,872,959.60                283,071,570.84
综合收益总

公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波

                                      母公司利润表
编制单位: 上海医药集团股份有限公司
                                                       单位:元 币种:人民币 审计类型:未经审计
                           本期金额         上期金额       年初至报告期期 上年年初至报告期期
           项目
                         (7-9 月)      (7-9 月)      末金额(1-9 月)  末金额(1-9 月)
 一、营业收入                189,391.00       214,551.00         568,092.00        611,655.00
     减:营业成本

                                           11
601607,02607                                           上海医药集团股份有限公司 2012 年第三季度报告



          营业税金及附
                                21,341.66         10,992.14         401,985.40              102,107.41
 加
         销售费用
         管理费用        50,086,090.22  46,853,894.57  123,940,572.66                  103,907,398.20
         财务费用        20,371,521.67  50,655,277.14 -171,383,612.56                   85,599,776.36
         资产减值损失
    加:公允价值变动
收益(损失以“-”号
填列)
         投资收益(损
                       418,883,649.78 202,133,646.67   524,846,057.49                  466,371,843.43
失以“-”号填列)
           其中:对联
营企业和合营企业的投     31,706,361.10  29,150,643.81  107,493,334.39                  100,394,601.34
资收益
二、营业利润(亏损以
                       348,594,087.23 104,828,033.82   572,455,203.99                  277,374,216.46
“-”号填列)
    加:营业外收入        4,951,199.88  19,198,892.84    11,108,968.38                  20,236,832.01
    减:营业外支出           30,398.74        -100.00        30,398.74
       其中:非流动资
产处置损失
三、利润总额(亏损总
                       353,514,888.37 124,027,026.66   583,533,773.63                  297,611,048.47
额以“-”号填列)
    减:所得税费用     -38,164,713.10 -11,649,253.88        818,019.33                 -38,059,690.00
四、净利润(净亏损以
                       391,679,601.47 135,676,280.54   582,715,754.30                  335,670,738.47
“-”号填列)
五、每股收益:
    (一)基本每股收

    (二)稀释每股收

六、其他综合收益           -113,558.22    -206,676.01      -205,540.41                 -61,252,413.30
七、综合收益总额       391,566,043.25 135,469,604.53   582,510,213.89                  274,418,325.17
公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波

4.3
                                       合并现金流量表
                                       2012 年 1—9 月
编制单位: 上海医药集团股份有限公司
                                                       单位:元 币种:人民币 审计类型:未经审计
                                                       年初至报告期期末金 上年年初至报告期期
                         项目
                                                           额(1-9 月)      末金额(1-9 月)
 一、经营活动产生的现金流量:
     销售商品、提供劳务收到的现金                        53,999,730,759.99       43,010,737,601.90
     客户存款和同业存放款项净增加额
     向中央银行借款净增加额
     向其他金融机构拆入资金净增加额
     收到原保险合同保费取得的现金
     收到再保险业务现金净额
     保户储金及投资款净增加额
     处置交易性金融资产净增加额

                                             12
601607,02607                                        上海医药集团股份有限公司 2012 年第三季度报告



     收取利息、手续费及佣金的现金
     拆入资金净增加额
     回购业务资金净增加额
     收到的税费返还                                      62,603,659.05           65,516,036.76
     收到其他与经营活动有关的现金                       772,380,380.69          742,070,413.83
        经营活动现金流入小计                         54,834,714,799.73       43,818,324,052.49
     购买商品、接受劳务支付的现金                    47,695,049,198.63       38,845,228,399.64
     客户贷款及垫款净增加额
     存放中央银行和同业款项净增加额
     支付原保险合同赔付款项的现金
     支付利息、手续费及佣金的现金
     支付保单红利的现金
     支付给职工以及为职工支付的现金                   2,079,997,175.53        1,603,560,672.66
     支付的各项税费                                   1,833,235,287.75        1,306,334,219.79
     支付其他与经营活动有关的现金                     2,519,221,971.40        1,609,869,577.01
        经营活动现金流出小计                         54,127,503,633.31       43,364,992,869.10
          经营活动产生的现金流量净额                    707,211,166.42          453,331,183.39
 二、投资活动产生的现金流量:
     收回投资收到的现金                                                          305,745,266.35
     取得投资收益收到的现金                              112,338,240.83          174,420,356.48
     处置固定资产、无形资产和其他长期资产收回的现
                                                          74,574,326.45           37,570,367.73
 金净额
     处置子公司及其他营业单位收到的现金净额               78,919,622.15         -214,477,138.00
     收到其他与投资活动有关的现金                         20,232,216.10          346,817,443.61
        投资活动现金流入小计                             286,064,405.53          650,076,296.17
     购建固定资产、无形资产和其他长期资产支付的现
                                                         447,898,775.68          287,669,246.43
 金
     投资支付的现金                                                              437,043,275.00
     质押贷款净增加额
     取得子公司及其他营业单位支付的现金净额             421,891,836.70        2,547,747,779.55
     支付其他与投资活动有关的现金                        72,865,249.08            6,064,383.92
        投资活动现金流出小计                            942,655,861.46        3,278,524,684.90
          投资活动产生的现金流量净额                   -656,591,455.93       -2,628,448,388.73
 三、筹资活动产生的现金流量:
     吸收投资收到的现金                                  50,526,309.00       13,370,647,277.79
     其中:子公司吸收少数股东投资收到的现金              50,526,309.00           46,315,963.00
     取得借款收到的现金                               6,371,195,499.23        7,861,781,101.26
     发行债券收到的现金
     收到其他与筹资活动有关的现金                        26,884,786.20           88,699,101.12
        筹资活动现金流入小计                          6,448,606,594.43       21,321,127,480.17
     偿还债务支付的现金                               7,178,706,831.14        9,810,524,227.03
     分配股利、利润或偿付利息支付的现金                 928,215,015.15          764,675,877.73
     其中:子公司支付给少数股东的股利、利润              89,426,527.17          150,582,051.36
     支付其他与筹资活动有关的现金                        61,449,978.90          300,399,432.42
        筹资活动现金流出小计                          8,168,371,825.19       10,875,599,537.18
          筹资活动产生的现金流量净额                 -1,719,765,230.76       10,445,527,942.99
 四、汇率变动对现金及现金等价物的影响                    51,705,831.01         -191,272,912.44
 五、现金及现金等价物净增加额                        -1,617,439,689.26        8,079,137,825.21
     加:期初现金及现金等价物余额                    14,554,707,997.90        6,210,448,737.91


                                           13
601607,02607                                        上海医药集团股份有限公司 2012 年第三季度报告



六、期末现金及现金等价物余额                          12,937,268,308.64      14,289,586,563.12
公司法定代表人: 周杰 主管会计工作负责人:徐国雄    会计机构负责人:沈波

                                     母公司现金流量表
                                       2012 年 1—9 月
编制单位: 上海医药集团股份有限公司
                                                         单位:元 币种:人民币 审计类型:未经审计
                                                         年初至报告期期末   上年年初至报告期
                        项目
                                                           金额(1-9 月)   期末金额(1-9 月)
一、经营活动产生的现金流量:
     销售商品、提供劳务收到的现金                          568,092.00                 591,655.00
     收到的税费返还
     收到其他与经营活动有关的现金                      409,240,840.02            366,927,298.68
       经营活动现金流入小计                            409,808,932.02            367,518,953.68
     购买商品、接受劳务支付的现金
     支付给职工以及为职工支付的现金                     37,512,673.73             34,645,079.59
     支付的各项税费                                      7,825,917.95              9,068,433.61
     支付其他与经营活动有关的现金                      398,088,135.01            157,049,552.08
       经营活动现金流出小计                            443,426,726.69            200,763,065.28
         经营活动产生的现金流量净额                    -33,617,794.67            166,755,888.40
二、投资活动产生的现金流量:
     收回投资收到的现金                                                          135,833,801.03
     取得投资收益收到的现金                            413,050,979.76            314,937,891.91
     处置固定资产、无形资产和其他长期资产收回的现金
                                                                                       50,000.00
净额
     处置子公司及其他营业单位收到的现金净额             41,170,000.00             12,882,045.12
     收到其他与投资活动有关的现金
       投资活动现金流入小计                            454,220,979.76           463,703,738.06
     购建固定资产、无形资产和其他长期资产支付的现金     38,707,708.11            33,633,156.22
     投资支付的现金                                                           3,637,127,635.00
     取得子公司及其他营业单位支付的现金净额            241,723,862.31
     支付其他与投资活动有关的现金                    3,003,980,000.00
       投资活动现金流出小计                          3,284,411,570.42         3,670,760,791.22
         投资活动产生的现金流量净额                 -2,830,190,590.66        -3,207,057,053.16
三、筹资活动产生的现金流量:
     吸收投资收到的现金                                                      13,324,331,314.79
     取得借款收到的现金                                360,000,000.00           800,000,000.00
     发行债券收到的现金
     收到其他与筹资活动有关的现金                                                42,500,000.00
       筹资活动现金流入小计                            360,000,000.00        14,166,831,314.79
     偿还债务支付的现金                                906,000,000.00            20,000,000.00
     分配股利、利润或偿付利息支付的现金                463,889,010.64           331,856,262.71
     支付其他与筹资活动有关的现金                       33,204,905.70           258,798,479.05
       筹资活动现金流出小计                          1,403,093,916.34           610,654,741.76
         筹资活动产生的现金流量净额                 -1,043,093,916.34        13,556,176,573.03
四、汇率变动对现金及现金等价物的影响                    45,574,821.41          -178,750,954.50
五、现金及现金等价物净增加额                        -3,861,327,480.26        10,337,124,453.77
     加:期初现金及现金等价物余额                    8,608,621,502.40           245,270,866.66
六、期末现金及现金等价物余额                         4,747,294,022.14        10,582,395,320.43
公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波

                                            14
数据加载中...
prevnext
手机查看股票